Last update 16 May 2025

Plasmin

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Fibrinogenase Injection, 纤溶酶注射液
Target
Fibrinogen x Plasminogen activators
Action
inhibitors, modulators
Mechanism
Fibrinogen inhibitors, Plasminogen activators modulators
Therapeutic Areas
Nervous System DiseasesCardiovascular DiseasesOther Diseases
Active Indication
Brain InfarctionThromboangiitis ObliteransThrombotic cerebral infarction
Inactive Indication-
Originator Organization
Beijing Science Sun Pharmaceutical Co., Ltd.Beijing Science Sun Pharmaceutical Co., Ltd.
Active Organization
Jilin Jinsheng Pharmaceutical Co. Ltd.Jilin Jinsheng Pharmaceutical Co. Ltd.Beijing Science Sun Pharmaceutical Co., Ltd.Beijing Science Sun Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1999),
Thromboangiitis ObliteransThrombotic cerebral infarction
Regulation-
Login to view timeline

Related

100 Clinical Results associated with Plasmin
Login to view more data
100 Translational Medicine associated with Plasmin
Login to view more data
100 Patents (Medical) associated with Plasmin
Login to view more data
18
Literatures (Medical) associated with Plasmin
01 Dec 2023Ophthalmic surgery, lasers & imaging retina
A Literary Pediatric Retina Fellowship With Michael T. Trese, MD
01 Feb 2013Retina (Philadelphia, Pa.)Q2 · MEDICINE
MICROPLASMIN (OCRIPLASMIN) IN PEDIATRIC VITREORETINAL SURGERY
Q2 · MEDICINE
01 Aug 2011American journal of ophthalmology
Intravitreal Injection of Autologous Plasmin Enzyme for Macular Edema Associated With Branch Retinal Vein Occlusion
100 Deals associated with Plasmin
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Brain Infarction
China
Jilin Jinsheng Pharmaceutical Co. Ltd.Jilin Jinsheng Pharmaceutical Co. Ltd.
22 May 2003
Thromboangiitis Obliterans
China
Beijing Science Sun Pharmaceutical Co., Ltd.Beijing Science Sun Pharmaceutical Co., Ltd.
01 Jan 1999
Thrombotic cerebral infarction
China
Beijing Science Sun Pharmaceutical Co., Ltd.Beijing Science Sun Pharmaceutical Co., Ltd.
01 Jan 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
PA022 (AAO2008)
Not Applicable
Diabetic macular oedema
-
vythcjzwjl(lwegfcowrj) = nlswyvxchi zyntsdvknx (ysbfsxfchg, 0.24)
View more
Positive
09 Nov 2008
ARVO2005
Not Applicable
Diabetic macular oedema
8
Autologous Plasmin Injection
xsqnqawhpb(rkfyhzwuoc) = mild inflammation was observed in one patient injected with 2.0 IU of plasmin, but the inflammation was resolved within 3 days qmsfuhuhqj (xzogvbdxho )
View more
Positive
01 May 2005
AAO2000
Not Applicable
Diabetic Retinopathy
-
Autologous Plasmin Enzyme (APE)
qzztakjeng(eyectwahth) = qnytpntwjl abapfyvoge (jszmaznkxw )
Positive
23 Oct 2000
qzztakjeng(eyectwahth) = izstwlvqub abapfyvoge (jszmaznkxw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free